Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report

The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE:MRK) drugs with potential blockbuster sales.Merck's cholesterol treatment enlicitide decanoate and cancer therapy sacituzumab tirumotecan (sac-TMT) have been reportedly selected for the FDA Commissioner's National Priority Voucher (CNPV) program, which accelerates regulatory decisions for medicines deemed critical to public health or national interests.If finalized, the drugs would becom ...